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Purpose: Polymerase chain reaction (PCR) assay, introduced
as a fast and sensitive diagnostic method, is useful in detecting
Mycobacterium tuberculosis. The purpose of this study was to
evaluate the usefulness of in-house PCR assay in the detection
of Mycobacterium tuberculosis by comparing PCR results with
conventional diagnostic techniques and Cobas Amplicor M.
tuberculosis
TM kit. Materials and Methods: We retrospectively
assessed the diagnostic yield of in-house PCR method
employed for the amplification IS6110 sequences in 2,973
specimens. We also compared in-house PCR with Cobas
Amplicor M. tuberculosis
TM kit in 120 specimens collected
from June to July 2006. Routine acid-fast stain (AFS) and
culture assay were also performed and analyzed. Results: Of
2,973 cases, 2,832 cases (95.3%) showed consistent results
between in house PCR, AFS and culture methods, whereas
141 (4.7%) displayed inconsistent results. The sensitivities,
specificities, and positive and negative predictive values of
each method were as follows: 77.5%, 99.7%, 95.5%, and
98.0%, respectively for PCR; 49.2%, 100%, 100%, and 95.7%,
respectively, for AFS method; and 80.7%, 100%, 100%, and
98.3%, respectively, for culture assay. Consistent results
between PCR and Cobas Amplicor M. tuberculosis
TM kit were
shown in 109 cases (90.8%). The sensitivities, specificities,
and positive and negative predictive values of each method
were as follows: 81.3%, 98.9%, 96.3%, and 93.5% respectively
for PCR and 71.9%, 100%, 100%, and 90.7%, respectively,
for Cobas Amplicor
TM kit. Conclusion: In-house PCR and
Cobas Amplicor
TM kit show high sensitivity and specificity,
and are reliable tests in the diagnosis of tuberculosis.
Key Words: Mycobacterium tuberculosis, in-house polymerase
chain reaction assay, Cobas Amplicor M. tuberculosis
TM kit
INTRODUCTION
Tuberculosis is a pandemic and highly con-
tagious disease. Of 6.1 billion world population, 2
billion people, which are approximately one-third
of the entire population, have been infected with
Mycobactericum tuberculosis, and 1% of the
population is being introduced as carriers every
year. Of these carriers, 7 - 8 million people develop
tuberculosis and 2 million die of the disease.
1 In
Korea, the incidence of tuberculosis was 72.1 in
100,000 in the year 2001, decreased to 67.2 in 2002,
64.0 in 2003, and then slightly increased to 65.4 in
2004.
2 Death from tuberculosis in Korea was 6.7
in 100,000 in the year 2001, 7.0 in 2002, and 6.9
in 2003.
3
Due to the world wide increase in the incidences
of immune-related diseases such as acquired
immunodeficiency syndrome (AIDS), the incidence
of tuberculosis is also being increased. In that
context, Korea is no exception, therefore more
prompt and accurate diagnosis of tuberculosis is
required.
4
Diagnosis of tuberculosis consists of signs and
symptoms, X-ray findings, and detection of M.
tuberculosis. Currently, bacterial culture, AFS, and
PCR are employed to isolate M. tuberculosis.
Bacterial culture method is feasible only if > 100
M. tuberculosis are present in 1 mL of specimen.
Although the specificity of the culture method is
close to 100% so as to be used for final diagnosis,
3 - 8 weeks are required to cultivate the bacteria.
The culture method is also not cost efficient.
5-8
AFS is a relatively fast simple procedure and cost
efficient. Nevertheless, it needs 5,000-10,000 bacteria
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present in 1 mL of sample and does not discrimi-
nate M. tuberculosis against other non-tuberculosis
mycobacteria, leading to low sensitivity (22 -
78%).
5-8 PCR detects M. tuberculosis directly in the
specimen and does not require weeks-long in-
cubation time so as to be fit for early diagnosis.
The disadvantage of PCR method is that it detects
not only viable M. tuberculosis but non-viable M.
tuberculosis. Thus, the method is not used for
definitive diagnosis.
5,9-11 Moreover, variations in
diagnostic procedures and specimens lead to
different rate of specificity between different
labs.
12-20
Given the above mentioned information, this
study was designed to evaluate in-house PCR
method by comparing it with conventional AFS,
bacterial culture method, and commonly used
Cobas Amplicor M. tuberculosis
TM kit (Roche
Molecular System, Inc., Branchburg, NJ, USA).
MATERIALS AND METHODS
Patients
In this study, we retrospectively analyzed the
results of in-house PCR, AFS, and culture for
tuberculosis diagnosis in 2,973 patients who
visited Kyung Hee Medical Center between July
2003 and July 2006. We also compared 29 in-house
PCR positive and 91 in-house PCR negative cases
(total 120 cases) between April 2006 and July 2006
with commercially available Cobas Amplicor M.
tuberculosis
TM kit, AFS, and culture.
Specimens
Sputum, bronchial aspirate, pleural fluid, urine,
cerebrospinal fluid, tissue, and other body fluid
were analyzed. Sputum, bronchial aspirate, urine,
and pus were incubated for 15 minutes at room
temperature in 4% NaOH and then centrifuged
for 15 - 20 minutes at 3000 g. Tissues were minced
with scissors, to which 1 mL of K buffer and 300
g/mL μ proteinase K were added and incubated
for 3 hours at 55°C. After heating for 10 minutes
at 95°C and centrifugation for 5 minutes at 7000g,
2 L of supernatant were collected and analyzed. μ
Cerebrospinal and other body fluid were
centrifuged without any pretreatmet.
AFS
Fluorochrome-stain positive specimens were
Ziehl-Neelsen stained and the results were then
determined under 1,000 × magnification with > 300
field according to classification of the Center for
Disease Control.
21
Culture of Mycobacterium tuberculosis
Specimens were inoculated onto 3% Ogawa
media and then incubated for at least 8 weeks at
37°C. Specimens were observed once every week.
In-house PCR
Samples were collected in Tris ethylenedia-
minetetraacetic acid (EDTA) [10 mM Tris-HCl
([H 8.0], 1 mM EDTA), centrifuged twice at 7000
rpm for 5 minutes. After discarding supernatant,
samples were heated for 10 minutes in 5% Chelex
50- 200 L and Tris EDTA buffer and centrifuged μ
at 12,000rpm for 5minutes. Two L of supernatant μ
was added to 20 L of reaction mixture [14 μ L μ
sterilized water, 2 L PCR buffer, 3.0 μ mM MgCl2,
0.8 L 2.5 μ mM deoxynucleoside triphosphate (Core
Biosystem, Seoul, Korea), loading dye 1 L, Taq μ
Table 1. Primer Sequences of In-house PCR for Detection of Mycobacterium tuberculosis
Name Function Position of IS6110 Sequences (5' 3') à
TB1 Primer for 1st PCR 555 - 572 CTCAAGGAGCACATCAGC
TB2 Primer for 1st PCR 1111 - 1084 TCATAGGAGCTTCCGACC
TB3 Primer for 2nd PCR 590 - 609 CTACGGTGTTTACGGTGCCC
TB4 Primer for 2nd PCR 874 - 855 TAGGCGTCGGTGACAAAGGC
PCR, polymerase chain reaction.Comparison of Methods for Detection of M. tuberculosis
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DNA polymerase (Core Biosystem, Seoul, Korea)
0.1 L 1.0 μ L μ primers (Bioneer, Daejeon, Korea)]
and amplified (GeneAmp PCR system 9600;
Perkin-Elmer Medical Instruments, CT, USA)
with 30 cycles at 94°C for 20 seconds, 60°C for
20 seconds, and 72°C for 30 seconds. Primer
sequences are shown in Table 1. Two L of 10 μ
times-diluted PCR product was again amplified
with the same condition at the first PCR. PCR
product (285 bp) was checked for size by com-
paring positive M. tuberculosis using 2% agarose
gel electrophoresis. To minimize cross-contamina-
tion, DNA extraction and amplification were
performed in separate rooms.
Cobas Amplicor M. tuberculosis
TM
DNA extraction and amplification were per-
formed according to the manufacturer's instruc-
tions.
Diagnosis of tuberculosis
Tuberculosis was diagnosed when culture was
positive. Culture negative tuberculosis was also
diagnosed based on positive results of other
diagnostic methods such as AFS and PCR. In
addition, clinical signs, X-ray and hemological
findings, and responses to anti-tuberculosis drugs
were also considered.
7,8,22 Culture-positive non-
tuberculosis Mycobacterium was excluded.
RESULTS
Analysis of in-house PCR, AFS, and culture
Of 2,973 samples, pulmonary samples were
1,134 (38.1%) [sputum 864 (29.0%), bronchial
aspirates 271 (9.1%)] non-pulmonary samples
were 1,839 (61.9%) of which pleural fluid was 834
(28.1%) (Table 2). Of pulmonary samples, 212
Table 2. Diagnostic Results of In-house PCR, AFB Stain, and Culture
Type of sample
Total no. of
samples (%)
Positive samples (n)
AFB stain Culture In-house PCR
Pulmonary specimens 1,134 (38.1)
Sputum 863 (29.0) 70 111 93
Bronchial aspirate 271 (9.1) 10 18 26
Extrapulmonary specimens 1,839 (61.9)
Pleural fluid 834 (28.1) 14 30 27
Cerebrospinal fluid 313 (10.5) 0 0 1
Urine 248 (8.3) 6 12 15
Tissue 147 (4.9) 6 8 8
Pus 109 (3.7) 13 16 25
Peritoneal fluid 59 (2.0) 0 1 0
Blood 34 (1.1) 0 0 0
Gastric aspirate 12 (0.4) 0 0 0
Pericardial fluid 9 (0.3) 0 0 0
Bone marrow 7 (0.2) 0 0 0
Other 67 (2.3) 1 0 3
Total 2,973 (100.0) 120 197 198
PCR, polymerase chain reaction; AFB, acid fast bacilli.Myeong-Hee Kim, et al.
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(18.7%) were positive for in-house PCR, 80 (7.1%)
for AFS, and 129 (11.4%) for culture. Of non-
pulmonary samples, 79 (4.3%) were positive for
in-house PCR, 40 (2.2%) for AFS, and 67 (3.6%)
for culture (Table 2). Of 2,973, 244 cases (8.2%)
were diagnosed as tuberculosis, 112 of which
were consistently positive for AFS, culture, and
PCR (Table 3). Of 132 cases that displayed
inconsistent results in AFS, culture, and PCR, 123
were finally diagnosed as tuberculosis and the
remaining 9 were diagnosed as pneumonia (2),
bronchiectasia (2), chronic obstructive pulmonary
diseases (2), esophageal cancer (1), peripartum
infection (1), and bronchitis (1). The 9 cases were
all positive for in-house PCR (Table 4). The
sensitivities for in-house PCR, AFS, and culture
were 77.5%, 49.2%, and 80.7%, respectively, and
specificities were 99.7%, 100%, and 100%,
respectively (Table 5).
Analysis of in-house PCR and Cobas Amplicor M.
tuberculosis
TM kit
Of 120 samples, pulmonary samples were 81
(67.5%) and non-pulmonary samples were 39
(32.5%). Of pulmonary samples, 17 (21.0%) were
positive for in-house PCR and 20 (24.7%) for
Cobas Amplicor
TM. Of non-pulmonary samples, 10
(25.6%) were positive for in-house PCR and 3
(7.7%) for Cobas Amplicor
TM (Table 6). Nineteen
cases were consistently positive in both in-house
PCR and Cobas Amplicor
TM, and 3 were con-
sistently negative. Inconsistent results were found
in 10 cases, of which 9 (3 sputum samples posi-
tive for Cobas Amplicor
TM and 2 pleural fluid, 2
urine, and 2 tissue samples positive for in-house
PCR) were diagnosed as tuberculosis and 1 as
chronic obstructive pulmonary disease (1 sputum
sample weakly positive for in-house PCR). The
Table 4. Final Diagnosis
AFB stain Culture In-house PCR No. of cases (%) Final diagnosis (no. of cases)
- + + 30 (21.3) Tuberculosis (30)
+ - + 2 (1.4) Tuberculosis (2)
+ + - 6 (4.3) Tuberculosis (6)
- + - 49 (34.8) Tuberculosis (49)
- - + 54 (38.3) Tuberculosis (45)
Pneumonia (2)
Bronchiectasis (2)
COPD (2)
Esophageal cancer (1)
Bronchitis (1)
Puerperal sepsis (1)
AFB, acid fast bacilli; PCR, polymerase chain reaction; COPD, chronic obstructive pulmonary disease.
Table 5. Sensitivities, Specificities, and Positive and Negative Predictabilities of In-house PCR, AFB Stain, and
Culture
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
AFB stain 49.2 100.0 100.0 95.7
Culture 80.7 100.0 100.0 98.3
In-house PCR 77.5 99.7 95.5 98.0
PCR, polymerase chain reaction; AFB, acid fast bacilli; PPV, positive predictability; NPV, negative predictability.Comparison of Methods for Detection of M. tuberculosis
Yonsei Med J Vol. 49, No. 4, 2008
sensitivities of in-house PCR and Cobas Amplicor
TM
were 81.3% and 71.9%, respectively (pulmonary
samples, 77.3% and 90.9%. non-pulmonary samples,
90.0% and 30.0%, respectively) (Table 7).
DISCUSSION
Diagnosis of tuberculosis usually includes
clinical symptoms, X-ray findings, and detection
of M. tuberculosis. To detect M. tuberculosis in
clinical samples, laboratory employs AFS, culture
of M. tuberculosis, and PCR. AFS is fast but the
sensitivity is low whereas culture of M. tuberculosis
needs long turnover time but sensitivity and
specificity are high. PCR assay, the sensitivity and
specificity of which are high and widely used in
many clinical laboratories, requires only very
small amounts of M. tuberculosis to diagnose
tuberculosis.
Table 7. Sensitivities, Specificities, and Positive and Negative Predictabilities of In-house PCR, Cobas Amplicor
M. tuberculosis
TM Kit, AFB Stain, and Culture in Pulmonary and Non-Pulmonary Samples
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
AFB stain 35.5 100.0 100.0 80.6
Culture 74.2 100.0 100.0 91.7
In-house PCR 81.3 98.9 96.3 93.5
Pulmonary samples 77.3 100.0 100.0 92.2
Non-pulmonary samples 90.0 96.6 90.0 96.6
Cobas Amplicor
TM 71.9 100.0 100.0 90.7
Pulmonary samples 90.9 100.0 100.0 96.7
Non-pulmonary samples 30.0 100.0 100.0 80.6
PCR, polymerase chain reaction; AFB, acid fast bacilli; PPV, positive predictability; NPV, negative predictability.
Table 6. Diagnostic Results of In-house PCR, Cobas Amplicor
TM, AFB Stain, and Culture in Pulmonary and
Non-pulmonary Samples
Type of sample
Total no. of samples
(%)
Positive samples (n)
AFB stain Culture In-house PCR
Cobas
Amplicor
TM
Pulmonary specimens 81 (67.5)
Sputum 65 (54.2) 10 15 14 17
Bronchial aspirate 15 (12.5) 0 3 2 2
Lung 1 (0.8) 0 1 1 1
Extrapulmonary specimens 39 (32.5)
Pleural fluid 25 (20.8) 0 1 3 0
Urine 8 (6.7) 0 3 4 2
Tissue 1 (0.8) - - 1 0
Gastric aspirate 1 (0.8) 0 0 0 0
Stool 1 (0.8) 1 0 1 1
Other 3 (2.5) 0 0 1 0
Total 120 (100.0) 11 23 27 23
PCR, polymerase chain reaction; AFB, acid fast bacilli.Myeong-Hee Kim, et al.
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In a study by 6 laboratories AFS, culture, and
PCR were analyzed, and the pooled sensitivities
were found to be 55.5%, 89.3%, 85.2%, respec-
tively, and pooled specificity was 99.7% for all 3
diagnostic methods.
22 Our study showed that the
sensitivities for AFS, culture, and PCR were
49.2%, 80.7%, 77.5%, respectively, and specificities
were 100%, 100%, and 99.7%, respectively, in-
dicating lower sensitivity and higher specificity.
Another study demonstrated that the sensitivities
for AFS, culture, and PCR were 41.3%, 65.7%, and
59%, respectively, which are lower than those in
our study and the specificities > 97%, and also
demonstrated that PCR in combination with AFS
increased sensitivity up to 65%, which is similar
to that of culture method, suggesting the possi-
bility for standard diagnostic procedure for tuber-
culosis.
7 Given the high sensitivity and specificity
of PCR method, we suggest that PCR is very
useful for the diagnosis of tuberculosis, except
when drug sensitivity and detection of non-
tuberculosis mycobacteria are required. PCR may
be used in AFB smear-positive samples for final
diagnosis of tuberculosis.
8
Nine false-positive results were found with
in-house PCR in this study. Two were pneumonia,
2 bronchiectasia, 2 chronic obstructive pulmonary
diseases, 1 esophageal cancer, 1 peripartum infec-
tion and 1 bronchitis. False positive may be caused
by the contamination of amplicons.
9,23-25 The
contamination is even higher in in-house PCR,
which requires multiple steps of specimen
processing procedures than in commercial kit.
23
False positive may also be caused by the fact that
PCR can not distinguish between viable and
non-viable M. tuberculosis.
9,23-25
Fifty-five cases in this study were found to be
false negative. False negative may be caused by
the presence of inhibitors, loss of M. tuberculosis
during DNA extraction procedures, and amplifi-
cation methods.
9,25 Since this is a retrospective
study, determination of the causes of false-
positive and false-negative results is limited.
The sensitivity and specificity estimates for
in-house PCR vary widely, ranging from 63 - 100%
for the sensitivity and 62 - 100% for the specificity.
5,26-34 The difference in the sensitivity of PCR may
be due to analytical sensitivity of PCR, PCR assay
shows difference in sensitivity depending on the
target of PCR and whether it is nested PCR or not.
In particular, high sensitivity was obtained when
IS6110 was the target. In addition, the distribution
of positive samples in the specimen, especially in
weak positive samples,
5 affects the sensitivity of
PCR, particularly contamination by amplicon.
34
In this study, the sensitivity and specificity
were 81.3% and 98.9% in in-house PCR and 71.9%
and 100% in Cobas Amplicor M. tuberculosis
TM kit,
indicating higher sensitivity and lower specificity
in in-house PCR. Intriguingly, when samples were
subdivided into pulmonary and non-pulmonary,
non-pulmonary samples showed lower sensitivity
(30%) than pulmonary samples (Table 7). This
result is not in line with a study in which
diagnostic results of in-house PCR and Cobas
Amplicor M. tuberculosis
TM kit in pulmonary and
non-pulmonary samples were analyzed.
20 The
reason of why inconsistent results were observed
in our study could be due to the fact that the
amount of specimens was inadequate or specimens
were weakly positive for M. tuberculosis.
35
Another study in which diagnostic results of in-
house PCR and Cobas Amplicor M. tuberculosis
TM
were analyzed demonstrated sensitivities of
91.08% and 66.33% for in-house PCR and Cobas
Amplicor M. tuberculosis
TM kit and specificities of
99.85% and 99.71%,
35 which are similar to our
results. Lower sensitivity in Cobas Amplicor M.
tuberculosis
TM kit may be attributed to the use of
single copy and ELISA or smaller amount of
sample (0.1 mL in Cobas Amplicor
TM and 1.0 mL
in in-house PCR). The possibility that lower
sensitivitiy in Cobas Amplicor M. tuberculosis
TM kit
may be due to the presence of inhibitors has also
been suggested.
36
Our laboratory employed nested PCR that
requires 2 rounds of amplification procedure and
confirmed PCR products not by Southern blotting
but agarose gel electrophoresis. Thus, different
primers, the amount of samples, and amplification
method might have affected sensitivity. As demon-
strated by the manufacturer, Cobas Amplicor
TM
displayed significantly lower sensitivity in non-
pulmonary samples and higher sensitivity in
pulmonary samples than in-house PCR (p < 0.01).
More samples and further followup are required
for in-depth study, nevertheless we suggest that
Cobas Amplicor
TM is a useful and time-efficientComparison of Methods for Detection of M. tuberculosis
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diagnostic method.
In summary, despite the high false-positive
diagnostic results, we demonstrated that in-house
PCR at Kyung Hee Medical Center can be used
in place of AFS and culture for the early diagnosis
of tuberculosis. Furthermore, in-house PCR showed
higher sensitivity in non-pulmonary samples than
Cobas Amplicor
TM kit. Cobas Amplicor
TM kit is
time efficient and has the advantage of lower
false-positive rates in the diagnosis of tuber-
culosis.
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